{ "title": "GLP-1 receptor agonist (public encyclopedia provenance reconstruction)", "therapyArea": "Metabolic", "finding": "Reconstructed from 22 public encyclopedia revisions showing article evolution", "provenance": { "sourceArtifacts": [ { "artifactId": "wp-revision-155043478", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 155043478)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=155043478", "version": "155043478", "publicationDate": "2023-11-12", "effectiveDate": "2023-11-12", "retrievalUrl": "", "summary": "Article revision 155043478", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-263707661", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 263707661)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=263707661", "version": "263707661", "publicationDate": "", "effectiveDate": "", "retrievalUrl": "", "summary": "Article revision 263707661", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-263709179", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 263709179)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=263709179", "version": "263709179", "publicationDate": "2009-01-13", "effectiveDate": "2009-01-13", "retrievalUrl": "", "summary": "Article revision 263709179", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-340144048", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 340144048)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=340144048", "version": "340144048", "publicationDate": "2010-01-26", "effectiveDate": "2010-01-26", "retrievalUrl": "", "summary": "Article revision 340144048", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-340380764", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 340380764)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=340380764", "version": "340380764", "publicationDate": "2010-01-27", "effectiveDate": "2010-01-27", "retrievalUrl": "", "summary": "Article revision 340380764", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-375719592", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 375719592)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=375719592", "version": "375719592", "publicationDate": "2010-07-27", "effectiveDate": "2010-07-27", "retrievalUrl": "", "summary": "Article revision 375719592", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-375720137", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 375720137)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=375720137", "version": "375720137", "publicationDate": "2010-07-27", "effectiveDate": "2010-07-27", "retrievalUrl": "", "summary": "Article revision 375720137", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-376097562", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 376097562)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=376097562", "version": "376097562", "publicationDate": "2010-07-29", "effectiveDate": "2010-07-29", "retrievalUrl": "", "summary": "Article revision 376097562", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-376545040", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 376545040)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=376545040", "version": "376545040", "publicationDate": "2010-08-01", "effectiveDate": "2010-08-01", "retrievalUrl": "", "summary": "Article revision 376545040", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-378969788", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 378969788)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=378969788", "version": "378969788", "publicationDate": "2010-08-15", "effectiveDate": "2010-08-15", "retrievalUrl": "", "summary": "Article revision 378969788", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-381484818", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 381484818)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=381484818", "version": "381484818", "publicationDate": "2010-08-28", "effectiveDate": "2010-08-28", "retrievalUrl": "", "summary": "Article revision 381484818", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-431589914", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 431589914)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=431589914", "version": "431589914", "publicationDate": "2011-05-30", "effectiveDate": "2011-05-30", "retrievalUrl": "", "summary": "Article revision 431589914", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-473982337", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 473982337)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=473982337", "version": "473982337", "publicationDate": "2012-01-30", "effectiveDate": "2012-01-30", "retrievalUrl": "", "summary": "Article revision 473982337", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-473982354", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 473982354)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=473982354", "version": "473982354", "publicationDate": "2012-01-30", "effectiveDate": "2012-01-30", "retrievalUrl": "", "summary": "Article revision 473982354", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-507804539", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 507804539)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=507804539", "version": "507804539", "publicationDate": "2012-08-17", "effectiveDate": "2012-08-17", "retrievalUrl": "", "summary": "Article revision 507804539", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-507804625", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 507804625)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=507804625", "version": "507804625", "publicationDate": "", "effectiveDate": "", "retrievalUrl": "", "summary": "Article revision 507804625", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-507804668", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 507804668)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=507804668", "version": "507804668", "publicationDate": "2012-08-17", "effectiveDate": "2012-08-17", "retrievalUrl": "", "summary": "Article revision 507804668", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-508640987", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 508640987)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=508640987", "version": "508640987", "publicationDate": "2012-08-22", "effectiveDate": "2012-08-22", "retrievalUrl": "", "summary": "Article revision 508640987", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-514900148", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 514900148)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=514900148", "version": "514900148", "publicationDate": "2012-09-27", "effectiveDate": "2012-09-27", "retrievalUrl": "", "summary": "Article revision 514900148", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-533124612", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 533124612)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=533124612", "version": "533124612", "publicationDate": "2013-01-15", "effectiveDate": "2013-01-15", "retrievalUrl": "", "summary": "Article revision 533124612", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-545542133", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 545542133)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=545542133", "version": "545542133", "publicationDate": "2013-03-19", "effectiveDate": "2013-03-19", "retrievalUrl": "", "summary": "Article revision 545542133", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-507804629", "artifactType": "other", "issuer": "public encyclopedia", "title": "GLP-1 receptor agonist (revision 507804629)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=GLP-1%20receptor%20agonist&oldid=507804629", "version": "507804629", "publicationDate": "2012-08-17", "effectiveDate": "2012-08-17", "retrievalUrl": "", "summary": "Article revision 507804629", "contentHash": "", "ingestedAt": "2026-06-17", "epistemicStatus": "directly-observed" } ], "sourceAssertions": [ { "assertionId": "assert-one-of-their-advantages-is-that-they-have-a-lower-risk-of-ca", "artifactId": "wp-revision-263709179", "exactText": "One of their advantages is that they have a lower risk of causing hypoglycemia", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2009-01-13", "epistemicStatus": "extracted" }, { "assertionId": "assert-licenced-exenatide-2005-under-investigation-liraglutide-albi", "artifactId": "wp-revision-263709179", "exactText": "Licenced : exenatide (2005)\n\nUnder investigation : liraglutide, albiglutide, taspoglutide\n\n==References==", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2009-01-13", "epistemicStatus": "extracted" }, { "assertionId": "assert-licenced-exenatide-under-investigation-liraglutide-albigluti", "artifactId": "wp-revision-263709179", "exactText": "Licenced : exenatide\n\nUnder investigation : liraglutide, albiglutide\n\n==References==", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2009-01-13", "epistemicStatus": "extracted" }, { "assertionId": "assert-licenced-exenatide-2005-under-investigation-albiglutide-tasp", "artifactId": "wp-revision-340144048", "exactText": "Licenced : exenatide (2005)\n\nUnder investigation : albiglutide, taspoglutide\n\n==References==", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2010-01-26", "epistemicStatus": "extracted" }, { "assertionId": "assert-licenced-exenatide-2005-liraglutide-2010-under-investigation", "artifactId": "wp-revision-340380764", "exactText": "Licenced : exenatide (2005), liraglutide (2010)\n\nUnder investigation : albiglutide, taspoglutide\n\n==References==", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2010-01-27", "epistemicStatus": "extracted" }, { "assertionId": "assert-one-of-their-advantages-over-insulin-is-that-they-have-a-low", "artifactId": "wp-revision-375719592", "exactText": "One of their advantages (over insulin?) is that they have a lower risk of causing hypoglycemia", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2010-07-27", "epistemicStatus": "extracted" }, { "assertionId": "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-new-clas", "artifactId": "wp-revision-507804539", "exactText": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are new classes of drugs for the treatment of type 2 diabetes", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2012-08-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-licensed-glp-1-agonists-exenatide-licensed-2005-liraglutide-", "artifactId": "wp-revision-507804539", "exactText": "Licensed GLP-1 agonists: exenatide (licensed 2005), liraglutide (licensed 2010)\n\nUnder investigation: albiglutide, taspoglutide, AVE0010", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2012-08-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-glucagon-like-peptide-1-analogs-are-a-new-class-of-drug-for-", "artifactId": "wp-revision-507804539", "exactText": "Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2012-08-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-new-cl", "artifactId": "wp-revision-507804668", "exactText": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a new class of drug for the treatment of type 2 diabetes", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2012-08-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-one-of-their-advantages-over-older-insulin-secretagogues-suc", "artifactId": "wp-revision-508640987", "exactText": "One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2012-08-22", "epistemicStatus": "extracted" }, { "assertionId": "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-class-", "artifactId": "wp-revision-514900148", "exactText": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a class of drugs for the treatment of type 2 diabetes", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2012-09-27", "epistemicStatus": "extracted" }, { "assertionId": "assert-licensed-glp-1-agonists-exenatide-byetta-licensed-in-2005-li", "artifactId": "wp-revision-514900148", "exactText": "Licensed GLP-1 agonists:\n* exenatide (Byetta), licensed in 2005\n* liraglutide (Victoza), licensed 2010\n\nUnder investigation: albiglutide, taspoglutide, AVE0010", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2012-09-27", "epistemicStatus": "extracted" } ], "claimFamilies": [ { "familyId": "fam-sentence-1", "familyName": "One of their advantages is that they have a lower risk of ca...", "keyAssertions": [ "assert-one-of-their-advantages-is-that-they-have-a-lower-risk-of-ca", "assert-one-of-their-advantages-over-insulin-is-that-they-have-a-low", "assert-one-of-their-advantages-over-older-insulin-secretagogues-suc" ], "variants": [ { "variantId": "var-fam-sentence-1-1", "variantName": "One of their advantages is that they have a lower risk of ca...", "proposition": "One of their advantages is that they have a lower risk of causing hypoglycemia", "provenance": { "sourceAssertionId": "assert-one-of-their-advantages-is-that-they-have-a-lower-risk-of-ca", "artifactId": "wp-revision-263709179", "location": { "section": "(lead)" }, "extractedAt": "2009-01-13", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-1-2", "variantName": "One of their advantages (over insulin?) is that they have a ...", "proposition": "One of their advantages (over insulin?) is that they have a lower risk of causing hypoglycemia", "provenance": { "sourceAssertionId": "assert-one-of-their-advantages-over-insulin-is-that-they-have-a-low", "artifactId": "wp-revision-375719592", "location": { "section": "(lead)" }, "extractedAt": "2010-07-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-1-3", "variantName": "One of their advantages over older insulin secretagogues, su...", "proposition": "One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia", "provenance": { "sourceAssertionId": "assert-one-of-their-advantages-over-older-insulin-secretagogues-suc", "artifactId": "wp-revision-508640987", "location": { "section": "(lead)" }, "extractedAt": "2012-08-22", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-1-1", "toVariantId": "var-fam-sentence-1-2", "confidence": "medium", "relationshipBasis": "Content change: refinement", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-1-2", "toVariantId": "var-fam-sentence-1-3", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" } ] }, { "familyId": "fam-sentence-2", "familyName": "Licenced : exenatide (2005)\n\nUnder investigation : liragluti...", "keyAssertions": [ "assert-licenced-exenatide-2005-under-investigation-liraglutide-albi", "assert-licenced-exenatide-under-investigation-liraglutide-albigluti", "assert-licenced-exenatide-2005-under-investigation-albiglutide-tasp", "assert-licenced-exenatide-2005-liraglutide-2010-under-investigation", "assert-licenced-exenatide-2005-liraglutide-2010-under-investigation", "assert-licensed-glp-1-agonists-exenatide-licensed-2005-liraglutide-", "assert-licensed-glp-1-agonists-exenatide-byetta-licensed-in-2005-li" ], "variants": [ { "variantId": "var-fam-sentence-2-1", "variantName": "Licenced : exenatide (2005)\n\nUnder investigation : liragluti...", "proposition": "Licenced : exenatide (2005)\n\nUnder investigation : liraglutide, albiglutide, taspoglutide\n\n==References==", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-2005-under-investigation-liraglutide-albi", "artifactId": "wp-revision-263709179", "location": { "section": "(lead)" }, "extractedAt": "2009-01-13", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-2", "variantName": "Licenced : exenatide\n\nUnder investigation : liraglutide, alb...", "proposition": "Licenced : exenatide\n\nUnder investigation : liraglutide, albiglutide\n\n==References==", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-under-investigation-liraglutide-albigluti", "artifactId": "wp-revision-263709179", "location": { "section": "(lead)" }, "extractedAt": "2009-01-13", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-3", "variantName": "Licenced : exenatide (2005)\n\nUnder investigation : albigluti...", "proposition": "Licenced : exenatide (2005)\n\nUnder investigation : albiglutide, taspoglutide\n\n==References==", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-2005-under-investigation-albiglutide-tasp", "artifactId": "wp-revision-340144048", "location": { "section": "(lead)" }, "extractedAt": "2010-01-26", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-4", "variantName": "Licenced : exenatide (2005), liraglutide (2010)\n\nUnder inves...", "proposition": "Licenced : exenatide (2005), liraglutide (2010)\n\nUnder investigation : albiglutide, taspoglutide\n\n==References==", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-2005-liraglutide-2010-under-investigation", "artifactId": "wp-revision-340380764", "location": { "section": "(lead)" }, "extractedAt": "2010-01-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-5", "variantName": "Licenced : exenatide (2005), liraglutide (2010)\n\nUnder inves...", "proposition": "Licenced : exenatide (2005), liraglutide (2010)\n\nUnder investigation : albiglutide, taspoglutide, AVE0010", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-2005-liraglutide-2010-under-investigation", "artifactId": "wp-revision-375720137", "location": { "section": "(lead)" }, "extractedAt": "2010-07-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-6", "variantName": "Licensed GLP-1 agonists: exenatide (licensed 2005), liraglut...", "proposition": "Licensed GLP-1 agonists: exenatide (licensed 2005), liraglutide (licensed 2010)\n\nUnder investigation: albiglutide, taspoglutide, AVE0010", "provenance": { "sourceAssertionId": "assert-licensed-glp-1-agonists-exenatide-licensed-2005-liraglutide-", "artifactId": "wp-revision-507804539", "location": { "section": "(lead)" }, "extractedAt": "2012-08-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-7", "variantName": "Licensed GLP-1 agonists:\n* exenatide (Byetta), licensed in 2...", "proposition": "Licensed GLP-1 agonists:\n* exenatide (Byetta), licensed in 2005\n* liraglutide (Victoza), licensed 2010\n\nUnder investigation: albiglutide, taspoglutide, AVE0010", "provenance": { "sourceAssertionId": "assert-licensed-glp-1-agonists-exenatide-byetta-licensed-in-2005-li", "artifactId": "wp-revision-514900148", "location": { "section": "(lead)" }, "extractedAt": "2012-09-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "narrows", "fromVariantId": "var-fam-sentence-2-1", "toVariantId": "var-fam-sentence-2-2", "confidence": "medium", "relationshipBasis": "Content change: removal", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-2-2", "toVariantId": "var-fam-sentence-2-3", "confidence": "medium", "relationshipBasis": "Content change: refinement", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-2-3", "toVariantId": "var-fam-sentence-2-4", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-2-4", "toVariantId": "var-fam-sentence-2-5", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-2-5", "toVariantId": "var-fam-sentence-2-6", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-2-6", "toVariantId": "var-fam-sentence-2-7", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" } ] }, { "familyId": "fam-sentence-3", "familyName": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are new cl...", "keyAssertions": [ "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-new-clas", "assert-glucagon-like-peptide-1-analogs-are-a-new-class-of-drug-for-", "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-new-cl", "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-class-" ], "variants": [ { "variantId": "var-fam-sentence-3-1", "variantName": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are new cl...", "proposition": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are new classes of drugs for the treatment of type 2 diabetes", "provenance": { "sourceAssertionId": "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-new-clas", "artifactId": "wp-revision-507804539", "location": { "section": "(lead)" }, "extractedAt": "2012-08-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-2", "variantName": "Glucagon-like peptide-1 analogs are a new class of drug for ...", "proposition": "Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes", "provenance": { "sourceAssertionId": "assert-glucagon-like-peptide-1-analogs-are-a-new-class-of-drug-for-", "artifactId": "wp-revision-507804539", "location": { "section": "(lead)" }, "extractedAt": "2012-08-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-3", "variantName": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a new ...", "proposition": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a new class of drug for the treatment of type 2 diabetes", "provenance": { "sourceAssertionId": "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-new-cl", "artifactId": "wp-revision-507804668", "location": { "section": "(lead)" }, "extractedAt": "2012-08-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-4", "variantName": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a clas...", "proposition": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a class of drugs for the treatment of type 2 diabetes", "provenance": { "sourceAssertionId": "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-class-", "artifactId": "wp-revision-514900148", "location": { "section": "(lead)" }, "extractedAt": "2012-09-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "narrows", "fromVariantId": "var-fam-sentence-3-1", "toVariantId": "var-fam-sentence-3-2", "confidence": "medium", "relationshipBasis": "Content change: removal", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-3-2", "toVariantId": "var-fam-sentence-3-3", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-3-3", "toVariantId": "var-fam-sentence-3-4", "confidence": "medium", "relationshipBasis": "Content change: refinement", "epistemicStatus": "inferred" } ] } ], "claimVariants": [ { "variantId": "var-fam-sentence-1-1", "variantName": "One of their advantages is that they have a lower risk of ca...", "proposition": "One of their advantages is that they have a lower risk of causing hypoglycemia", "provenance": { "sourceAssertionId": "assert-one-of-their-advantages-is-that-they-have-a-lower-risk-of-ca", "artifactId": "wp-revision-263709179", "location": { "section": "(lead)" }, "extractedAt": "2009-01-13", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-1-2", "variantName": "One of their advantages (over insulin?) is that they have a ...", "proposition": "One of their advantages (over insulin?) is that they have a lower risk of causing hypoglycemia", "provenance": { "sourceAssertionId": "assert-one-of-their-advantages-over-insulin-is-that-they-have-a-low", "artifactId": "wp-revision-375719592", "location": { "section": "(lead)" }, "extractedAt": "2010-07-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-1-3", "variantName": "One of their advantages over older insulin secretagogues, su...", "proposition": "One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia", "provenance": { "sourceAssertionId": "assert-one-of-their-advantages-over-older-insulin-secretagogues-suc", "artifactId": "wp-revision-508640987", "location": { "section": "(lead)" }, "extractedAt": "2012-08-22", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-1", "variantName": "Licenced : exenatide (2005)\n\nUnder investigation : liragluti...", "proposition": "Licenced : exenatide (2005)\n\nUnder investigation : liraglutide, albiglutide, taspoglutide\n\n==References==", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-2005-under-investigation-liraglutide-albi", "artifactId": "wp-revision-263709179", "location": { "section": "(lead)" }, "extractedAt": "2009-01-13", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-2", "variantName": "Licenced : exenatide\n\nUnder investigation : liraglutide, alb...", "proposition": "Licenced : exenatide\n\nUnder investigation : liraglutide, albiglutide\n\n==References==", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-under-investigation-liraglutide-albigluti", "artifactId": "wp-revision-263709179", "location": { "section": "(lead)" }, "extractedAt": "2009-01-13", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-3", "variantName": "Licenced : exenatide (2005)\n\nUnder investigation : albigluti...", "proposition": "Licenced : exenatide (2005)\n\nUnder investigation : albiglutide, taspoglutide\n\n==References==", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-2005-under-investigation-albiglutide-tasp", "artifactId": "wp-revision-340144048", "location": { "section": "(lead)" }, "extractedAt": "2010-01-26", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-4", "variantName": "Licenced : exenatide (2005), liraglutide (2010)\n\nUnder inves...", "proposition": "Licenced : exenatide (2005), liraglutide (2010)\n\nUnder investigation : albiglutide, taspoglutide\n\n==References==", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-2005-liraglutide-2010-under-investigation", "artifactId": "wp-revision-340380764", "location": { "section": "(lead)" }, "extractedAt": "2010-01-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-5", "variantName": "Licenced : exenatide (2005), liraglutide (2010)\n\nUnder inves...", "proposition": "Licenced : exenatide (2005), liraglutide (2010)\n\nUnder investigation : albiglutide, taspoglutide, AVE0010", "provenance": { "sourceAssertionId": "assert-licenced-exenatide-2005-liraglutide-2010-under-investigation", "artifactId": "wp-revision-375720137", "location": { "section": "(lead)" }, "extractedAt": "2010-07-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-6", "variantName": "Licensed GLP-1 agonists: exenatide (licensed 2005), liraglut...", "proposition": "Licensed GLP-1 agonists: exenatide (licensed 2005), liraglutide (licensed 2010)\n\nUnder investigation: albiglutide, taspoglutide, AVE0010", "provenance": { "sourceAssertionId": "assert-licensed-glp-1-agonists-exenatide-licensed-2005-liraglutide-", "artifactId": "wp-revision-507804539", "location": { "section": "(lead)" }, "extractedAt": "2012-08-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-7", "variantName": "Licensed GLP-1 agonists:\n* exenatide (Byetta), licensed in 2...", "proposition": "Licensed GLP-1 agonists:\n* exenatide (Byetta), licensed in 2005\n* liraglutide (Victoza), licensed 2010\n\nUnder investigation: albiglutide, taspoglutide, AVE0010", "provenance": { "sourceAssertionId": "assert-licensed-glp-1-agonists-exenatide-byetta-licensed-in-2005-li", "artifactId": "wp-revision-514900148", "location": { "section": "(lead)" }, "extractedAt": "2012-09-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-1", "variantName": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are new cl...", "proposition": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are new classes of drugs for the treatment of type 2 diabetes", "provenance": { "sourceAssertionId": "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-new-clas", "artifactId": "wp-revision-507804539", "location": { "section": "(lead)" }, "extractedAt": "2012-08-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-2", "variantName": "Glucagon-like peptide-1 analogs are a new class of drug for ...", "proposition": "Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes", "provenance": { "sourceAssertionId": "assert-glucagon-like-peptide-1-analogs-are-a-new-class-of-drug-for-", "artifactId": "wp-revision-507804539", "location": { "section": "(lead)" }, "extractedAt": "2012-08-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-3", "variantName": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a new ...", "proposition": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a new class of drug for the treatment of type 2 diabetes", "provenance": { "sourceAssertionId": "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-new-cl", "artifactId": "wp-revision-507804668", "location": { "section": "(lead)" }, "extractedAt": "2012-08-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-4", "variantName": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a clas...", "proposition": "Glucagon-like peptide-1 agonists (GLP-1 agonists) are a class of drugs for the treatment of type 2 diabetes", "provenance": { "sourceAssertionId": "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-class-", "artifactId": "wp-revision-514900148", "location": { "section": "(lead)" }, "extractedAt": "2012-09-27", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relianceCommitments": [ { "commitmentId": "rely-cit-340380764-1", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.fda.gov", "title": "http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm", "stableIdentifier": "http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm" }, "commitmentDate": "2010-01-27", "confidence": "medium", "rationale": "citation_added in revision 340380764", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-375719592-2", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.medscape.com", "title": "Glucagon-like Peptide-1 Analogs Other Than Exenatide", "stableIdentifier": "http://www.medscape.com/viewarticle/578304" }, "commitmentDate": "2010-07-27", "confidence": "medium", "rationale": "citation_added in revision 375719592", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-375719592-3", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.fda.gov", "title": "FDA Approves New Treatment for Type 2 Diabetes", "stableIdentifier": "http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm" }, "commitmentDate": "2010-07-27", "confidence": "medium", "rationale": "citation_added in revision 375719592", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-375719592-4", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.medscape.com", "title": "http://www.medscape.com/viewarticle/578304", "stableIdentifier": "http://www.medscape.com/viewarticle/578304" }, "commitmentDate": "2010-07-27", "confidence": "medium", "rationale": "citation_removed in revision 375719592", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-375719592-5", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.fda.gov", "title": "http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm", "stableIdentifier": "http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm" }, "commitmentDate": "2010-07-27", "confidence": "medium", "rationale": "citation_removed in revision 375719592", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-375720137-6", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.medscape.com", "title": "http://www.medscape.com/viewarticle/578304", "stableIdentifier": "http://www.medscape.com/viewarticle/578304" }, "commitmentDate": "2010-07-27", "confidence": "medium", "rationale": "citation_added in revision 375720137", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-375720137-7", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.fda.gov", "title": "http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm", "stableIdentifier": "http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm" }, "commitmentDate": "2010-07-27", "confidence": "medium", "rationale": "citation_added in revision 375720137", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-375720137-8", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.medscape.com", "title": "Glucagon-like Peptide-1 Analogs Other Than Exenatide", "stableIdentifier": "http://www.medscape.com/viewarticle/578304" }, "commitmentDate": "2010-07-27", "confidence": "medium", "rationale": "citation_removed in revision 375720137", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-375720137-9", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.fda.gov", "title": "FDA Approves New Treatment for Type 2 Diabetes", "stableIdentifier": "http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm" }, "commitmentDate": "2010-07-27", "confidence": "medium", "rationale": "citation_removed in revision 375720137", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-508640987-10", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "public encyclopedia", "sourceArtifact": { "artifactType": "other", "issuer": "Unknown", "title": "Unnamed citation", "stableIdentifier": "" }, "commitmentDate": "2012-08-22", "confidence": "medium", "rationale": "citation_added in revision 508640987", "epistemicStatus": "inferred" }, { "epistemicStatus": "institution-confirmed", "commitmentId": "rely-fda-exenatide-t2d", "claimVariantId": "var-fam-sentence-3-3", "commitmentType": "operational-use", "committingInstitution": "FDA", "sourceArtifact": { "artifactType": "regulatory", "issuer": "U.S. Food and Drug Administration", "title": "Exenatide (Byetta) approval for type 2 diabetes, NDA 021773", "stableIdentifier": "https://www.accessdata.fda.gov/drugsatfda_docs/appletster/2005/021773s000ltr.pdf" }, "commitmentDate": "2005-04-28", "confidence": "high", "rationale": "FDA approval converts the evidence claim \"GLP-1 agonists are a class of drugs for type 2 diabetes\" into an operational regulatory commitment for exenatide." }, { "epistemicStatus": "institution-confirmed", "commitmentId": "rely-fda-liraglutide-t2d", "claimVariantId": "var-fam-sentence-2-6", "commitmentType": "operational-use", "committingInstitution": "FDA", "sourceArtifact": { "artifactType": "regulatory", "issuer": "U.S. Food and Drug Administration", "title": "Liraglutide (Victoza) approval for type 2 diabetes, NDA 022341", "stableIdentifier": "https://www.accessdata.fda.gov/drugsatfda_docs/applets/2010/022341s000TOC.cfm" }, "commitmentDate": "2010-01-25", "confidence": "high", "rationale": "FDA approval extends the operational commitment to another GLP-1 agonist, supporting the family that exenatide and liraglutide are licensed options." }, { "epistemicStatus": "inferred", "commitmentId": "rely-ada-ascvd", "claimVariantId": "var-fam-sentence-3-3", "commitmentType": "endorsement", "committingInstitution": "American Diabetes Association", "sourceArtifact": { "artifactType": "guideline", "issuer": "American Diabetes Association", "title": "Standards of Care in Diabetes — Glycemic Goals and Telehealth", "stableIdentifier": "https://diabetesjournals.org/care/issue/47/Supplement_1" }, "commitmentDate": "2024-01-01", "confidence": "medium", "rationale": "ADA Standards of Care endorse GLP-1 receptor agonists for type 2 diabetes, particularly when atherosclerotic cardiovascular disease is present. This is an endorsement inferred from guideline language, not an operational record of a specific institution acting on it." } ], "observedEvents": [ { "eventId": "evt-revert-473982354", "eventType": "status-change", "title": "Revert detected", "description": "Reverted edits by [[Special:Contributions/59.95.72.254|59.95.72.254]] ([[User talk:59.95.72.254|talk]]) to last revision by PhiLiP ([[WP:HG|HG]])", "occurredAt": "2012-01-30", "epistemicStatus": "directly-observed" }, { "eventId": "evt-move-155043478", "eventType": "artifact-updated", "title": "Page moved: GLP-1 receptor agonist → Draft:Move/Glucagon-like peptide-1 receptor agonist", "description": "from=GLP-1 receptor agonist to=Draft:Move/Glucagon-like peptide-1 receptor agonist comment=[[WP:PMRC#4|Round-robin history swap]] step 1 using [[:en:User:Ahecht/Scripts/pageswap.js|pageswap]]", "occurredAt": "2023-11-12", "epistemicStatus": "directly-observed" }, { "eventId": "evt-talk-507804629", "eventType": "status-change", "title": "Talk page correlation", "description": "time_delta_hours=0 talk_comment=Facts707 moved page [[Talk:Glucagon-like peptide-1 analog]] to [[Talk:Glucagon-like peptide-1 agonist]]: Technically drugs in this class are agonists, since they bind t", "occurredAt": "2012-08-17", "epistemicStatus": "directly-observed" }, { "eventId": "evt-talk-507804629", "eventType": "status-change", "title": "Talk page correlation", "description": "time_delta_hours=0 talk_comment=Facts707 moved page [[Talk:Glucagon-like peptide-1 analog]] to [[Talk:Glucagon-like peptide-1 agonist]]: Technically drugs in this class are agonists, since they bind t", "occurredAt": "2012-08-17", "epistemicStatus": "directly-observed" }, { "eventId": "evt-talk-507804629", "eventType": "status-change", "title": "Talk page correlation", "description": "time_delta_hours=0 talk_comment=Facts707 moved page [[Talk:Glucagon-like peptide-1 analog]] to [[Talk:Glucagon-like peptide-1 agonist]]: Technically drugs in this class are agonists, since they bind t", "occurredAt": "2012-08-17", "epistemicStatus": "directly-observed" }, { "eventId": "evt-talk-507804629", "eventType": "status-change", "title": "Talk page correlation", "description": "time_delta_hours=129.3 talk_comment=Facts707 moved page [[Talk:Glucagon-like peptide-1 analog]] to [[Talk:Glucagon-like peptide-1 agonist]]: Technically drugs in this class are agonists, since they bi", "occurredAt": "2012-08-17", "epistemicStatus": "directly-observed" }, { "eventId": "evt-fda-exenatide-approval", "eventType": "artifact-issued", "title": "FDA approves exenatide for type 2 diabetes", "description": "FDA approves exenatide (Byetta), the first GLP-1 receptor agonist, for type 2 diabetes treatment.", "occurredAt": "2005-04-28", "jurisdiction": "United States", "epistemicStatus": "directly-observed" }, { "eventId": "evt-fda-liraglutide-approval", "eventType": "artifact-issued", "title": "FDA approves liraglutide for type 2 diabetes", "description": "FDA approves liraglutide (Victoza), expanding the GLP-1 receptor agonist class for type 2 diabetes.", "occurredAt": "2010-01-25", "jurisdiction": "United States", "epistemicStatus": "directly-observed" }, { "eventId": "evt-ada-endorsement", "eventType": "guideline-updated", "title": "ADA Standards of Care endorse GLP-1 receptor agonists", "description": "American Diabetes Association Standards of Care recommend GLP-1 receptor agonists for type 2 diabetes, particularly in patients with atherosclerotic cardiovascular disease.", "occurredAt": "2024-01-01", "jurisdiction": "United States", "epistemicStatus": "directly-observed" } ], "eventImpacts": [ { "impactId": "impact-fam-sentence-1-modification", "claimFamilyId": "fam-sentence-1", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-one-of-their-advantages-is-that-they-have-a-lower-risk-of-ca", "assert-one-of-their-advantages-over-insulin-is-that-they-have-a-low", "assert-one-of-their-advantages-over-older-insulin-secretagogues-suc" ], "analysisDescription": "3 variants detected across revision history", "epistemicStatus": "inferred" }, { "impactId": "impact-fam-sentence-2-modification", "claimFamilyId": "fam-sentence-2", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-licenced-exenatide-2005-under-investigation-liraglutide-albi", "assert-licenced-exenatide-under-investigation-liraglutide-albigluti", "assert-licenced-exenatide-2005-under-investigation-albiglutide-tasp", "assert-licenced-exenatide-2005-liraglutide-2010-under-investigation", "assert-licenced-exenatide-2005-liraglutide-2010-under-investigation", "assert-licensed-glp-1-agonists-exenatide-licensed-2005-liraglutide-", "assert-licensed-glp-1-agonists-exenatide-byetta-licensed-in-2005-li" ], "analysisDescription": "7 variants detected across revision history", "epistemicStatus": "inferred" }, { "impactId": "impact-fam-sentence-3-modification", "claimFamilyId": "fam-sentence-3", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-new-clas", "assert-glucagon-like-peptide-1-analogs-are-a-new-class-of-drug-for-", "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-new-cl", "assert-glucagon-like-peptide-1-agonists-glp-1-agonists-are-a-class-" ], "analysisDescription": "4 variants detected across revision history", "epistemicStatus": "inferred" }, { "epistemicStatus": "inferred", "impactId": "impact-fda-exenatide-fam-3", "claimFamilyId": "fam-sentence-3", "eventId": "evt-fda-exenatide-approval", "impactType": "support-enhanced", "confidence": "high", "evidentiaryBasis": [ "rely-fda-exenatide-t2d" ], "analysisDescription": "FDA approval of exenatide operationalizes the class-level claim that GLP-1 agonists are drugs for type 2 diabetes." }, { "epistemicStatus": "inferred", "impactId": "impact-fda-liraglutide-fam-2", "claimFamilyId": "fam-sentence-2", "eventId": "evt-fda-liraglutide-approval", "impactType": "support-enhanced", "confidence": "high", "evidentiaryBasis": [ "rely-fda-liraglutide-t2d" ], "analysisDescription": "FDA approval of liraglutide updates the licensed-drug list claim family, confirming liraglutide as a licensed option." }, { "epistemicStatus": "inferred", "impactId": "impact-ada-endorsement-fam-3", "claimFamilyId": "fam-sentence-3", "eventId": "evt-ada-endorsement", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "rely-ada-ascvd" ], "analysisDescription": "ADA guideline endorsement strengthens the evidentiary basis for using GLP-1 agonists in T2D with ASCVD, adding a qualification to the class claim." } ], "reviewDecisions": [ { "decisionId": "decision-revert-473982354", "claimFamilyId": "fam-sentence-1", "eventId": "evt-revert-473982354", "decisionType": "reject", "rationale": "Reverted edits by [[Special:Contributions/59.95.72.254|59.95.72.254]] ([[User talk:59.95.72.254|talk]]) to last revision by PhiLiP ([[WP:HG|HG]])", "inputs": [ "evt-revert-473982354" ], "decidedAt": "2012-01-30", "confident": true, "epistemicStatus": "analyst-asserted" }, { "epistemicStatus": "analyst-asserted", "decisionId": "decision-fda-exenatide-adopt", "claimFamilyId": "fam-sentence-3", "eventId": "evt-fda-exenatide-approval", "decisionType": "adopt", "rationale": "FDA approval provides direct institutional operationalization of the class-level T2D claim.", "inputs": [ "impact-fda-exenatide-fam-3", "rely-fda-exenatide-t2d" ], "decidedAt": "2005-04-28", "decidedBy": "automated reviewer", "confident": true }, { "epistemicStatus": "analyst-asserted", "decisionId": "decision-fda-liraglutide-amend", "claimFamilyId": "fam-sentence-2", "eventId": "evt-fda-liraglutide-approval", "decisionType": "amend", "rationale": "Add liraglutide to the list of licensed GLP-1 agonists without changing the family scope.", "inputs": [ "impact-fda-liraglutide-fam-2", "rely-fda-liraglutide-t2d" ], "decidedAt": "2010-01-25", "decidedBy": "automated reviewer", "confident": true }, { "epistemicStatus": "analyst-asserted", "decisionId": "decision-ada-endorsement-retain", "claimFamilyId": "fam-sentence-3", "eventId": "evt-ada-endorsement", "decisionType": "retain-with-caveats", "rationale": "Endorsement supports the class claim but is inferred from guideline language, not an operational record; retain with ASCVD qualification.", "inputs": [ "impact-ada-endorsement-fam-3", "rely-ada-ascvd" ], "decidedAt": "2024-01-01", "decidedBy": "automated reviewer", "confident": false } ], "assessments": [ { "familyId": "fam-sentence-1", "direction": "disputed", "confidence": "high", "variantCount": 3, "netDirection": 0, "disputeCount": 1, "lastChangeAt": "2012-08-22", "summary": "3 variants, qualifies, qualifies, 1 dispute(s)", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-2", "direction": "mixed", "confidence": "medium", "variantCount": 7, "netDirection": -0.5, "disputeCount": 0, "lastChangeAt": "2012-09-27", "summary": "7 variants, narrows, qualifies, qualifies, qualifies, qualifies, qualifies", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-3", "direction": "mixed", "confidence": "medium", "variantCount": 4, "netDirection": -0.5, "disputeCount": 0, "lastChangeAt": "2012-09-27", "summary": "4 variants, narrows, qualifies, qualifies", "epistemicStatus": "analyst-asserted" } ] }, "classification": { "evidentiaryFields": [ "Public encyclopedia version identifiers", "Edit timestamps", "Editor usernames", "Edit comments", "Citation URLs", "Page move records", "Template changes" ], "derivedFields": [ "Sentence-level diffs (before/after)", "Citation added/removed events", "Section reorganization events", "Edit magnitude (minor/moderate/major)", "Content change type", "Key terms extraction", "Direction signal (strengthening/weakening/neutral)" ], "inferredFields": [ "Claim family membership", "Claim variant relationships", "Confidence assignment", "Impact direction", "Decision rationale reconstruction", "Reliance commitment interpretation" ], "illustrativeFields": [] }, "reproducibility": { "analysts": 2, "method": "Independent assertion extraction and claim-family grouping by two analysts, with disagreements resolved by documented criteria.", "familyOverlap": { "matched": 3, "total": 3, "ratio": 1 }, "variantOverlap": { "matched": 11, "total": 14, "ratio": 0.79 }, "documentedDisagreements": [ { "description": "Bridge process split a drug-list assertion into two families because word overlap fell below the 0.5 threshold; human analyst treated it as one semantic family.", "resolution": "Added section-anchored joining: merge assertions in the same section when overlap > 0.3." } ], "passed": true }, "crossSpecimenImpacts": [ { "impactId": "cross-glp1-liraglutide-obesity", "direction": "incoming", "targetSpecimenRoute": "/baselines/provenance/liraglutide/", "targetSpecimenTitle": "Liraglutide (public encyclopedia provenance reconstruction)", "targetClaimFamilyId": "fam-sentence-7", "sourceEventId": "evt-fda-liraglutide-obesity", "impactType": "support-enhanced", "confidence": "high", "rationale": "FDA approval of liraglutide for chronic weight management strengthens the cross-specimen claim that GLP-1-class drugs, including liraglutide, have an obesity/weight-management indication.", "sourceEventTitle": "FDA approves liraglutide for chronic weight management" }, { "impactId": "cross-glp1-liraglutide-t2d", "direction": "outgoing", "targetSpecimenRoute": "/baselines/provenance/liraglutide/", "targetSpecimenTitle": "Liraglutide (public encyclopedia provenance reconstruction)", "targetClaimFamilyId": "fam-sentence-3", "sourceEventId": "evt-ada-endorsement", "impactType": "support-enhanced", "confidence": "medium", "rationale": "The GLP-1 class ADA endorsement supports the liraglutide T2D mechanism claim because liraglutide is a member of the endorsed class.", "sourceEventTitle": "ADA Standards of Care endorse GLP-1 receptor agonists" } ] }